# Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD

> **NCT02937974** · PHASE4 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 254 (estimated)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Xuebijing
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02937974
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 254 (ESTIMATED)
- **Last updated:** 2016-10-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02937974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02937974, "Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT02937974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*